Aurinia Pharmaceuticals is a biopharma company focused on treatments for autoimmune kidney disease. Its lead commercial product, Lupkynis (voclosporin), is an oral calcineurin inhibitor approved for adults with active lupus nephritis, used alongside standard immunosuppressive therapy. The company markets primarily to nephrologists and rheumatologists treating systemic lupus erythematosus with renal involvement.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 70 | — | 21.5 | 1,404.2% |
| Q3 2025 | 73.5 | — | 31.6 | 120.7% |
| Q4 2025 | 77.1 | — | 210.8 | 14,622.4% |
| Q1 2026 | 77.7 | — | 34.4 | 56.3% |
| Q2 2026 | 83.2 | 18.9% | 37.4 | 73.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Addus HomeCare Corporation (ADUS), Hemab Therapeutics Holdings, Inc. (COAG), Stagwell Inc. (STGW), Midera Food Processing, Inc. (MFP), Alamar Biosciences, Inc. (ALMR), HUTCHMED (China) Limited (HCM)